Analysts have been eager to weigh in on the Healthcare sector with new ratings on VistaGen Therapeutics (VTGN – Research Report) and Humacyte (HUMA – Research Report).
VistaGen Therapeutics (VTGN)
Maxim Group analyst Jason McCarthy maintained a Hold rating on VistaGen Therapeutics yesterday. The company’s shares closed last Friday at $0.14, close to its 52-week low of $0.08.
According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
VistaGen Therapeutics has an analyst consensus of Hold.
See today’s best-performing stocks on TipRanks >>
Humacyte (HUMA)
In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Humacyte, with a price target of $8.00. The company’s shares closed last Friday at $2.84, close to its 52-week low of $1.96.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of
Currently, the analyst consensus on Humacyte is a Moderate Buy with an average price target of $8.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VTGN:
